Settara C Chandrasekharappa1, Steven B Chinn2, Frank X Donovan1, Naweed I Chowdhury3, Aparna Kamat1, Adebowale A Adeyemo4, James W Thomas5, Meghana Vemulapalli5, Caroline S Hussey6, Holly H Reid7, James C Mullikin5, Qingyi Wei8, Erich M Sturgis9,10. 1. Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland. 2. Department of Otolaryngology-Head and Neck Surgery, The University of Michigan, Ann Arbor, Michigan. 3. Department of Otolaryngology-Head and Neck Surgery, University of Kansas Medical Center, Kansas City, Kansas. 4. Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland. 5. Intramural Sequencing Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland. 6. The University of Texas Health Science Center School of Medicine, Houston, Texas. 7. Department of Dermatology, The University of Texas Health Science Center School of Medicine, Houston, Texas. 8. Department of Medicine, Duke University School of Medicine, Durham, North Carolina. 9. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. 10. Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: Patients with Fanconi anemia (FA) have an increased risk for head and neck squamous cell carcinoma (HNSCC). The authors sought to determine the prevalence of undiagnosed FA and FA carriers among patients with HNSCC as well as an age cutoff for FA genetic screening. METHODS: Germline DNA samples from 417 patients with HNSCC aged <50 years were screened for sequence variants by targeted next-generation sequencing of the entire length of 16 FA genes. RESULTS: The sequence revealed 194 FA gene variants in 185 patients (44%). The variant spectrum was comprised of 183 nonsynonymous point mutations, 9 indels, 1 large deletion, and 1 synonymous variant that was predicted to effect splicing. One hundred eight patients (26%) had at least 1 rare variant that was predicted to be damaging, and 57 (14%) had at least 1 rare variant that was predicted to be damaging and had been previously reported. Fifteen patients carried 2 rare variants or an X-linked variant in an FA gene. Overall, an age cutoff for FA screening was not identified among young patients with HNSCC, because there were no significant differences in mutation rates when patients were stratified by age, tumor site, ethnicity, smoking status, or human papillomavirus status. However, an increased burden, or mutation load, of FA gene variants was observed in carriers of the genes FA complementation group D2 (FANCD2), FANCE, and FANCL in the HNSCC patient cohort relative to the 1000 Genomes population. CONCLUSIONS: FA germline functional variants offer a novel area of study in HNSCC tumorigenesis. FANCE and FANCL, which are components of the core complex, are known to be responsible for the recruitment and ubiquitination, respectively, of FANCD2, a critical step in the FA DNA repair pathway. In the current cohort, the increased mutation load of FANCD2, FANCE, and FANCL variants among younger patients with HNSCC indicates the importance of the FA pathway in HNSCC. Cancer 2017;123:3943-54.
BACKGROUND:Patients with Fanconi anemia (FA) have an increased risk for head and neck squamous cell carcinoma (HNSCC). The authors sought to determine the prevalence of undiagnosed FA and FA carriers among patients with HNSCC as well as an age cutoff for FA genetic screening. METHODS: Germline DNA samples from 417 patients with HNSCC aged <50 years were screened for sequence variants by targeted next-generation sequencing of the entire length of 16 FA genes. RESULTS: The sequence revealed 194 FA gene variants in 185 patients (44%). The variant spectrum was comprised of 183 nonsynonymous point mutations, 9 indels, 1 large deletion, and 1 synonymous variant that was predicted to effect splicing. One hundred eight patients (26%) had at least 1 rare variant that was predicted to be damaging, and 57 (14%) had at least 1 rare variant that was predicted to be damaging and had been previously reported. Fifteen patients carried 2 rare variants or an X-linked variant in an FA gene. Overall, an age cutoff for FA screening was not identified among young patients with HNSCC, because there were no significant differences in mutation rates when patients were stratified by age, tumor site, ethnicity, smoking status, or humanpapillomavirus status. However, an increased burden, or mutation load, of FA gene variants was observed in carriers of the genes FA complementation group D2 (FANCD2), FANCE, and FANCL in the HNSCC patient cohort relative to the 1000 Genomes population. CONCLUSIONS: FA germline functional variants offer a novel area of study in HNSCC tumorigenesis. FANCE and FANCL, which are components of the core complex, are known to be responsible for the recruitment and ubiquitination, respectively, of FANCD2, a critical step in the FA DNA repair pathway. In the current cohort, the increased mutation load of FANCD2, FANCE, and FANCL variants among younger patients with HNSCC indicates the importance of the FA pathway in HNSCC. Cancer 2017;123:3943-54.
Authors: David Polito; Scott Cukras; Xiaozhe Wang; Paige Spence; Lisa Moreau; Alan D D'Andrea; Younghoon Kee Journal: J Biol Chem Date: 2014-01-22 Impact factor: 5.157
Authors: Nuria Seguí; Leonardo B Mina; Conxi Lázaro; Rebeca Sanz-Pamplona; Tirso Pons; Matilde Navarro; Fernando Bellido; Adriana López-Doriga; Rafael Valdés-Mas; Marta Pineda; Elisabet Guinó; August Vidal; José Luís Soto; Trinidad Caldés; Mercedes Durán; Miguel Urioste; Daniel Rueda; Joan Brunet; Milagros Balbín; Pilar Blay; Silvia Iglesias; Pilar Garré; Enrique Lastra; Ana Beatriz Sánchez-Heras; Alfonso Valencia; Victor Moreno; Miguel Ángel Pujana; Alberto Villanueva; Ignacio Blanco; Gabriel Capellá; Jordi Surrallés; Xose S Puente; Laura Valle Journal: Gastroenterology Date: 2015-06-05 Impact factor: 22.682
Authors: Advaitha Madireddy; Settapong T Kosiyatrakul; Rebecca A Boisvert; Emilia Herrera-Moyano; María L García-Rubio; Jeannine Gerhardt; Elizabeth A Vuono; Nichole Owen; Zi Yan; Susan Olson; Andrés Aguilera; Niall G Howlett; Carl L Schildkraut Journal: Mol Cell Date: 2016-10-20 Impact factor: 17.970
Authors: Settara C Chandrasekharappa; Francis P Lach; Danielle C Kimble; Aparna Kamat; Jamie K Teer; Frank X Donovan; Elizabeth Flynn; Shurjo K Sen; Supawat Thongthip; Erica Sanborn; Agata Smogorzewska; Arleen D Auerbach; Elaine A Ostrander Journal: Blood Date: 2013-04-23 Impact factor: 22.113
Authors: Edward C Stanley; Paul A Azzinaro; David A Vierra; Niall G Howlett; Steven Q Irvine Journal: Evol Bioinform Online Date: 2016-06-06 Impact factor: 1.625
Authors: Martine Froukje van der Kamp; Gyorgy Bela Halmos; Victor Guryev; Peter Laszlo Horvatovich; Ed Schuuring; Bernardus Franciscus Augustinus Maria van der Laan; Bert van der Vegt; Boudewijn Evert Christiaan Plaat; Cornelia Johanna Verhoeven Journal: Cell Oncol (Dordr) Date: 2022-01-11 Impact factor: 6.730
Authors: Caitlin T Fierheller; Laure Guitton-Sert; Wejdan M Alenezi; Timothée Revil; Kathleen K Oros; Yuandi Gao; Karine Bedard; Suzanna L Arcand; Corinne Serruya; Supriya Behl; Liliane Meunier; Hubert Fleury; Eleanor Fewings; Deepak N Subramanian; Javad Nadaf; Jeffrey P Bruce; Rachel Bell; Diane Provencher; William D Foulkes; Zaki El Haffaf; Anne-Marie Mes-Masson; Jacek Majewski; Trevor J Pugh; Marc Tischkowitz; Paul A James; Ian G Campbell; Celia M T Greenwood; Jiannis Ragoussis; Jean-Yves Masson; Patricia N Tonin Journal: Genome Med Date: 2021-12-03 Impact factor: 11.117
Authors: Caroline V M Verhagen; David M Vossen; Kerstin Borgmann; Floor Hageman; Reidar Grénman; Manon Verwijs-Janssen; Lisanne Mout; Roel J C Kluin; Marja Nieuwland; Tesa M Severson; Arno Velds; Ron Kerkhoven; Mark J O'Connor; Martijn van der Heijden; Marie-Louise van Velthuysen; Marcel Verheij; Volkert B Wreesmann; Lodewyk F A Wessels; Michiel W M van den Brekel; Conchita Vens Journal: Oncotarget Date: 2018-04-06